EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Non‐canonical function of transferrin receptor‐1 promotes breast cancer metastasis by activating HCK‒STAT3‒MMP9 signalling

Qing Zhao, Yafang Wang, Pengfei Wang, Yaqi Ding, Rong Wang, Yanyan Shen, Biyu Yang, Yanfen Fang, Jian Ding, Yi Chen

Clinical and Translational Medicine · 2026-07 · 16 (7)

DOI: 10.1002/ctm2.70731 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 12.07.2026. Verfasst von Qing Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nanchang University School of Pharmacy, Nanchang University, Nanchang, PR China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Breast Neoplasms, Receptors, Transferrin, Matrix Metalloproteinase 9. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chinese Academy of Sciences: Strategic Priority Research Program Grant, Department of Science and Technology of Shandong Province, China: Key R&D Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transferrin receptor 1 (TfR‐1), a key mediator of cellular iron uptake, is significantly upregulated across a broad spectrum of malignancies, and its overexpression highly correlated with poor clinical outcomes, such as in breast cancer. However, its precise role in breast cancer progression remains unclear.

Methods

We integrated clinical breast cancer tissue specimens and public transcriptomic datasets to analyse the clinical correlation between TfR‐1 expression and tumour metastasis. A series of in vitro cell functional assays and in vivo xenograft tumour metastasis models were performed to validate the regulatory effect of TfR‐1 on breast cancer proliferation and metastasis. Co‑immunoprecipitation, phosphorylation detection and protein stability assays were further applied to dissect the intermolecular regulatory network among TfR‐1, Hematopoietic Cell Kinase (HCK) and Ubiquitin Specific Peptidase 32 (USP32).

Results

Clinical data analysis revealed that elevated TfR‐1 expression was tightly linked to metastatic phenotype in breast cancer. Functional experiments confirmed that upregulated TfR‐1 robustly boosted the proliferative and metastatic capacity of breast cancer cells in vitro and in vivo. Mechanistically, TfR‐1 dual‑regulates HCK, it directly induces HCK phosphorylation, while simultaneously activating USP32 to block HCK protein degradation and sustain HCK abundance. Activated HCK further triggers STAT3 transcription factor signalling, which drives the upregulation and secretion of matrix metalloproteinase 9 (MMP9). In addition, HCK reciprocally phosphorylates TfR‐1 to establish a positive feedback circuit amplifying the prometastatic signalling.

Conclusions

This work identifies a previously uncharacterized prometastatic function of TfR‐1 independent of its canonical iron transport activity in breast cancer. We uncover a reciprocal TfR‑1/HCK positive feedback axis that activates the USP32‑HCK‑STAT3‑MMP9 signalling cascade to facilitate breast cancer metastasis, which provides novel candidate therapeutic targets for metastatic breast cancer intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorBreast NeoplasmsReceptors, TransferrinMatrix Metalloproteinase 9Antigens, CDHumansFemaleAnimalsSignal TransductionMiceNeoplasm MetastasisCell Line, Tumor

Stichwörter der Autor:innen

HCKSTAT3TfR‐1USP32breast cancermetastasis

Substanzen

STAT3 Transcription FactorReceptors, TransferrinMatrix Metalloproteinase 9STAT3 protein, humanCD71 antigenMMP9 protein, humanAntigens, CD

Autor:innen und Institutionen

  • Nanchang University School of Pharmacy, Nanchang University, Nanchang, PR China.
  • State Key Laboratory of Drug Research, Division of Antitumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China.
  • State Key Laboratory of Chemical Biology, Division of Antitumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China.
  • State Key Laboratory of Systems Medicine for Cancer and International Collaboration Cancer Center, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, PR China.

Förderung

  • National Natural Science Foundation of China
  • Chinese Academy of Sciences: Strategic Priority Research Program Grant
  • Department of Science and Technology of Shandong Province, China: Key R&D Program

Zitieren

APA

Zhao, Q., Wang, Y., Wang, P., Ding, Y., Wang, R., Shen, Y., Yang, B., Fang, Y., Ding, J., & Chen, Y. (2026). Non‐canonical function of transferrin receptor‐1 promotes breast cancer metastasis by activating HCK‒STAT3‒MMP9 signalling. Clinical and Translational Medicine, 16(7). https://doi.org/10.1002/ctm2.70731

Vancouver

Zhao Q, Wang Y, Wang P, Ding Y, Wang R, Shen Y, et al. Non‐canonical function of transferrin receptor‐1 promotes breast cancer metastasis by activating HCK‒STAT3‒MMP9 signalling. Clinical and Translational Medicine. 2026;16(7). doi:10.1002/ctm2.70731

BibTeX
@article{Zhao2026,
  author = {Zhao, Qing and Wang, Yafang and Wang, Pengfei and Ding, Yaqi and Wang, Rong and Shen, Yanyan and Yang, Biyu and Fang, Yanfen and Ding, Jian and Chen, Yi},
  title = {Non‐canonical function of transferrin receptor‐1 promotes breast cancer metastasis by activating HCK‒STAT3‒MMP9 signalling},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  volume = {16},
  number = {7},
  doi = {10.1002/ctm2.70731}
}
Kostenlos starten →